Intracranial pressure (ICP) is the pressure inside the skull, which can be measured in the ventricular system through a thin catheter inserted into the brain via burr holes. It is measured in millimeters of mercury (mm Hg). The ICP is normally 7 mmHg and varies with age, gender, posture, and respiration. It plays a very important role in maintaining the health and viability of the central nervous system. High intracranial pressure (above 20 mm Hg) has been linked to a number of neurological conditions including increased headaches, hydrocephalus, brain herniation, and even death. Elevated ICP is mostly caused by increased production and/or reduced absorption of cerebrospinal fluid (CSF). It is also a common symptom of abnormal intracranial circulation of blood, which can be caused by cerebral ischemia, stroke, and brain tumors. In the medical profession, it is considered important to monitor and manage ICP in order to avoid these complications and to ensure adequate oxygenation of the brain. ICP is monitored with a device called an intracranial pressure monitor, which is placed directly into the brain and monitored continuously. An individual’s ICP can also be monitored by a continuous EEG or ICP transducer. Managing ICP involves controlling factors that could possibly lead to increased ICP, such as maintaining adequate hydration and positioning the patient. It also involves medicines to reduce the amount of CSF produced by the body. In order to reduce the risk of adverse effects, a physician must take into account any other underlying conditions that the patient might have, as some treatments might be contraindicated. In conclusion, intracranial pressure is an extremely important part of maintaining a healthy central nervous system, and knowledge of this pressure is essential to providing the best patient care. The ability to accurately measure and manage it can reduce the risk of serious complications and ensure the highest quality of life.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States